Phocas Financial Corp’s iShares Biotechnology ETF IBB Stock Holding History

Phocas Financial Corp’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-430	Closed	-$56.5K	–	241
2022 Q4	$56.5K	Buy	+430	New	+$55.6K	0.01%	236
2019 Q2	–	Hold	0	–	–	–	196
2018 Q4	–	Hold	0	–	–	–	206

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Phocas Financial Corp's IBB Position: Q1 2023 in Review

Phocas Financial Corp sold out of iShares Biotechnology ETF (IBB) in Q1 2023, closing a stake of 430 shares — an estimated $56.5K sold.

Phocas Financial Corp first reported a position in IBB in Q4 2022 and held it in 1 quarter. The position peaked at $56.5K in Q4 2022. 866 funds tracked by Wall St. Rank hold IBB as of Q1 2023.

Phocas Financial Corp reported no remaining iShares Biotechnology ETF position as of Q1 2023 after selling out during the quarter.
Phocas Financial Corp sold 430 iShares Biotechnology ETF shares in Q1 2023, an estimated $56.5K.
Phocas Financial Corp first reported a position in iShares Biotechnology ETF in Q4 2022 and held it in 1 quarter.
Phocas Financial Corp's iShares Biotechnology ETF position peaked at $56.5K in Q4 2022.
866 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2023.

Based on Phocas Financial Corp's 13F filing for Q1 2023, filed 13 Apr 2023.